CDKN2A and glioblastoma: However, durable response in a Ink4a/Arf(−/−) EGFRvIII model was not observed until temozolomide (TMZ), a DNA alkylating agent and the standard-of-care chemotherapy for glioblastoma, was added to the regimen.